Massive Bio
Still Running· since Jul 18, 2026
- 74
- days running
- 0
- relaunches
Ad copy
For metastatic NSCLC with PD-L1 ≥50% and no actionable mutations, a first-line clinical trial is open. Refer appropriate patients today.
PD-L1 High NSCLC Trial
PD-L1 ≥50% | No actionable mutations | Treatment-naive advanced NSCLC.'
LEARN MORE🪄Crush AI
Like this ad? Make it yours.
Crush rebuilds this exact creative around your product — your brand, your colors, your offer — in about a minute.
